27791364|t|Albumin -Bioinspired Gd: CuS Nanotheranostic Agent for In Vivo Photoacoustic / Magnetic Resonance Imaging -Guided Tumor -Targeted Photothermal Therapy
27791364|a|Photothermal therapy (PTT) is attracting increasing interest and becoming more widely used for skin cancer therapy in the clinic, as a result of its noninvasiveness and low systemic adverse effects. However, there is an urgent need to develop biocompatible PTT agents, which enable accurate imaging, monitoring, and diagnosis. Herein, a biocompatible Gd -integrated CuS nanotheranostic agent (Gd: CuS @ BSA) was synthesized via a facile and environmentally friendly biomimetic strategy, using bovine serum albumin (BSA) as a biotemplate at physiological temperature. The as-prepared Gd: CuS @ BSA nanoparticles (NPs) with ultrasmall sizes (ca. 9 nm) exhibited high photothermal conversion efficiency and good photostability under near-infrared (NIR) laser irradiation. With doped Gd species and strong tunable NIR absorbance, Gd: CuS @ BSA NPs demonstrate prominent tumor-contrasted imaging performance both on the photoacoustic and magnetic resonance imaging modalities. The subsequent Gd: CuS @ BSA -mediated PTT result shows high therapy efficacy as a result of their potent NIR absorption and high photothermal conversion efficiency. The immune response triggered by Gd: CuS @ BSA -mediated PTT is preliminarily explored. In addition, toxicity studies in vitro and in vivo verify that Gd: CuS @ BSA NPs qualify as biocompatible agents. A biodistribution study demonstrated that the NPs can undergo hepatic clearance from the body. This study highlights the practicality and versatility of albumin -mediated biomimetic mineralization of a nanotheranostic agent and also suggests that bioinspired Gd: CuS @ BSA NPs possess promising imaging guidance and effective tumor ablation properties, with high spatial resolution and deep tissue penetration.
27791364	0	7	Albumin	T103	UMLS:C0001924
27791364	21	23	Gd	T103	UMLS:C0016911
27791364	25	28	CuS	T103	UMLS:C0056599
27791364	55	62	In Vivo	T082	UMLS:C1515655
27791364	63	76	Photoacoustic	T058	UMLS:C3897929
27791364	63	150	Photoacoustic / Magnetic Resonance Imaging -Guided Tumor -Targeted Photothermal Therapy	T058	UMLS:C0087111
27791364	79	105	Magnetic Resonance Imaging	T058	UMLS:C0024485
27791364	114	119	Tumor	T038	UMLS:C0027651
27791364	151	171	Photothermal therapy	T058	UMLS:C0087111
27791364	173	176	PTT	T058	UMLS:C0087111
27791364	246	250	skin	T022	UMLS:C1123023
27791364	246	265	skin cancer therapy	T058	UMLS:C0920425
27791364	273	279	clinic	T092	UMLS:C0442592
27791364	320	348	low systemic adverse effects	T038	UMLS:C0261794
27791364	442	449	imaging	T058	UMLS:C0011923
27791364	451	461	monitoring	T058	UMLS:C1283169
27791364	467	476	diagnosis	T033	UMLS:C0011900
27791364	502	504	Gd	T103	UMLS:C0016911
27791364	517	520	CuS	T103	UMLS:C0056599
27791364	544	546	Gd	T103	UMLS:C0016911
27791364	548	551	CuS	T103	UMLS:C0056599
27791364	554	557	BSA	T103	UMLS:C0036774
27791364	644	664	bovine serum albumin	T103	UMLS:C0036774
27791364	666	669	BSA	T103	UMLS:C0036774
27791364	734	736	Gd	T103	UMLS:C0016911
27791364	738	741	CuS	T103	UMLS:C0056599
27791364	744	747	BSA	T103	UMLS:C0036774
27791364	816	850	photothermal conversion efficiency	T033	UMLS:C0243095
27791364	860	874	photostability	T033	UMLS:C0243095
27791364	925	941	doped Gd species	T103	UMLS:C0016911
27791364	977	979	Gd	T103	UMLS:C0016911
27791364	981	984	CuS	T103	UMLS:C0056599
27791364	987	990	BSA	T103	UMLS:C0036774
27791364	1017	1041	tumor-contrasted imaging	T058	UMLS:C0011923
27791364	1066	1079	photoacoustic	T058	UMLS:C3897929
27791364	1084	1110	magnetic resonance imaging	T058	UMLS:C0024485
27791364	1138	1140	Gd	T103	UMLS:C0016911
27791364	1138	1165	Gd: CuS @ BSA -mediated PTT	T058	UMLS:C0087111
27791364	1142	1145	CuS	T103	UMLS:C0056599
27791364	1148	1151	BSA	T103	UMLS:C0036774
27791364	1184	1200	therapy efficacy	T033	UMLS:C0243095
27791364	1229	1243	NIR absorption	T033	UMLS:C0243095
27791364	1253	1287	photothermal conversion efficiency	T033	UMLS:C0243095
27791364	1293	1308	immune response	T038	UMLS:C0301872
27791364	1322	1324	Gd	T103	UMLS:C0016911
27791364	1322	1349	Gd: CuS @ BSA -mediated PTT	T058	UMLS:C0087111
27791364	1326	1329	CuS	T103	UMLS:C0056599
27791364	1332	1335	BSA	T103	UMLS:C0036774
27791364	1390	1406	toxicity studies	T058	UMLS:C0242890
27791364	1420	1427	in vivo	T082	UMLS:C1515655
27791364	1440	1442	Gd	T103	UMLS:C0016911
27791364	1444	1447	CuS	T103	UMLS:C0056599
27791364	1450	1453	BSA	T103	UMLS:C0036774
27791364	1493	1514	biodistribution study	T062	UMLS:C0242481
27791364	1580	1584	body	T204	UMLS:C0242821
27791364	1644	1651	albumin	T103	UMLS:C0001924
27791364	1750	1752	Gd	T103	UMLS:C0016911
27791364	1754	1757	CuS	T103	UMLS:C0056599
27791364	1760	1763	BSA	T103	UMLS:C0036774
27791364	1786	1802	imaging guidance	T058	UMLS:C0442972
27791364	1817	1842	tumor ablation properties	T058	UMLS:C0087111
27791364	1882	1888	tissue	T017	UMLS:C0040300